key: cord-0850398-wam1a4xa
authors: Soraas, A.; Grodeland, G.; Granerud, B. K.; Ueland, T.; Lind, A.; Fevang, B.; Murphy, S.; Huse, C.; Nygaard, A. B.; Steffensen, A. K.; al-Baldawi, H.; Holberg-Petersen, M.; Andresen, L. L.; Agnes, C.; Ranheim, T.; Schanke, Y.; Istre, M.; Dahl, J. A.; Chopra, A.; Dudman, S.; Kaarbo, M.; Andersen, J. T.; Vaage, E. B.; Tran, T. T.; Vaage, J. T.; Michelsen, A.; Muller, F.; Aukrust, P.; Halvorsen, B.; Dahl, T. B.; Holter, J. C.; Lund-Johansen, F.
title: Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
date: 2022-01-27
journal: nan
DOI: 10.1101/2022.01.27.22269895
sha: deb4a975471f838fc17be4dce6a616de17744585
doc_id: 850398
cord_uid: wam1a4xa

Background: The Omicron variant of SARS-CoV-2 is now overtaking the Delta variant in many countries. Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron may indicate that the higher rate of transmission is due to evasion from vaccine-induced immunity. However, there is little information about activation of recall responses to Omicron in vaccinated individuals. Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the SARS-CoV-2 spike and nucleocapsid proteins and spike peptide-induced interferon gamma in whole blood. Both the Omicron and the Delta infected patients had a mild and transient increase in inflammatory parameters. Interpretation: The results suggest that vaccine-induced immunological memory yields similar coverage for the Omicron and Delta variants.

The SARS-CoV-2 Omicron (B.1.1.529) variant is now dominating the pandemic in many countries. The virus harbors up to 36 mutations in the spike protein, which is the target of vaccine-induced neutralizing antibodies (https://covdb.stanford.edu/page/mutationviewer/#Omicron). Sera from individuals who have received two vaccine doses appear to have little or no neutralizing activity to Omicron, and early results from South Africa and the UK suggest that vaccine effectiveness against symptomatic disease with Omicron is significantly lower than with the Delta (B.1.617.2) variant. [1] [2] [3] [4] [5] [6] [7] There are now concerns that standard vaccine dose regimens may not provide sufficient protection, and that booster doses are necessary. While it seems possible that Omicron evades immunological memory established after vaccination, there is currently little knowledge about immune responses to Omicron infection. To assess re-activation of humoral immunological memory, we measured the early SARS-CoV-2 induced immune responses in twice vaccinated individuals infected with Omicron during an outbreak in Oslo in November 2021. 8 Double-vaccinated individuals infected with the Delta variant served as controls. We present data on viral load in nasopharynx, the initial general inflammatory response, antibodies to protein-and peptide antigens derived from SARS-CoV-2 and seasonal coronaviruses, and activation of spikespecific T cells as assessed by interferon (IFN)-γ in blood upon exposure to spike peptides. Freestanding follow up survey. 9 The samples were taken at the patients` home by an ambulant team, or at an outpatient clinic at Oslo University Hospital (OUH). Data on SARS-CoV-2 vaccination status were obtained from the Norwegian national mandatory registry on vaccination (SYSVAK).

Initially, a total of 41 Omicron suspected and 18 verified Delta variant cases were included in the study. Among 16 household members of Omicron suspected cases, 11 were considered Omicron suspected cases and included in the study according to the test criteria, thus ending with 52 cases in the Omicron group and 18 in the Delta group ( Table 1) . All suspected Omicron cases were verified by whole genome sequencing. 10 Household members who tested negative were included in the analysis of healthy controls (Supplemental Table 1 ).

Reference samples were also collected in the same period of time from 14 age and sexmatched vaccinated healthy controls who were recruited at the Research Institute of Internal -Medicine, OUH (supplemental Table 1 ).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Blood for routine biochemistry, SARS-CoV-2 specific antibodies, interferon gamma (IFN-γ) release assay (IGRA), and markers of immune activation and inflammation was taken at baseline within a median of 6 days after symptom onset (Table 1) , and at 1 week follow-up (4-6 days from inclusion). Samples were processed within 1.5 hour, or centrifuged at 2000g for 20 minutes at 4ºC (EDTA plasma; serum: 15 minutes at room temperature) and stored at -80ºC until further analysis.

Routine blood biochemistry including C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), haemoglobin, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), fibrinogen, procalcitonin (PCT), D-dimer, platelet count, total white blood cell (WBC) count, monocyte, neutrophil and lymphocyte count, immunoglobulin (Ig), troponin T (TnT), and N terminal pro-brain-natriuretic peptide (NT-proBNP) were analysed at Laboratory for Medical Biochemistry at OUH Rikshospitalet, Oslo, Norway. Plasma levels of soluble (s) CD14, sCD163, sCD25, soluble T cell immunoglobulin mucin domain-3 (sTIM-3), myeoloperoxidase (MPO), lipopolysaccharide (LPS) binding protein (LBP), IFNγ-induced protein (IP-10), pentraxin-3 (PTX-3), growth differentiation factor 15 (GDF-15), matrix metallopeptidase 9 (MMP-9), and S100 calcium-binding protein A12 (S100A12) were measured in duplicate by enzyme immunoassays (EIA) using commercially available antibodies (R&D Systems, Minneapolis, MN) in a 384 format using a combination of a All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The terminal complement complex TCC was measured with the same setup using a monoclonal antibody aE11 reacting with a neoepitope exposed in C9 when incorporated in TCC, in a modified version of the method described by Mollnes et al. 11, 12 A similar setup was used for von Willebrand factor (vWF) with antibodies from Dako Cytomation (Glostrup, Denmark) using parallel diluted human plasma as standard curve. Absorption was read at 450 nm with wavelength correction set to 540 nm using an EIA plate reader (BioTek). Samples from all patients and controls were run on the same 384-well plate and intra-assay coefficient of variation was <10%.

Antibodies to the nucleocapsid and RBD proteins derived from wild-type SARS-CoV-2 were measured with using a slightly modified version of a bead-based assay described previously. 13 Briefly, neutravidin-coupled polymer beads with fluorescent barcodes and biotinylated virus proteins were incubated for 1h with serum diluted 1:1000 or 1:10.000 at 22ºC. SARS-CoV-2 RBD ad full-length spike were obtained from Florian Krammer and Ian McLellan, respectively. 14,15 Spike proteins from seasonal coronaviruses were obtained from Ulrich Rothbauer. 16 Peptide antigens from SARS-CoV-2 were described previously. 17 The beads were washed twice with PBS containing 1% Tween 20 (PBT), and labelled with R-Phycoerythrin-conjugated anti-human IgG Fc or anti-human IgA Fc (Jackson Immunoresearch). Next, the beads were analyzed by flow cytometry. Antibody levels were measured as the R-Phycoerythrin median fluorescence intensity (MFI) of beads coupled with virus proteins divided by the signal measured for beads coupled with neutravidin only. A serum sample measured to contain 53000 Binding Antibody Units (BAU) with the Roche All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Elecsys assay was used to generate a standard curve to convert relative MFI values for IgG to BAU. 

The detection of SARS-CoV-2 CD4 and CD4/CD8 spike T cell responses was done using QuantiFERON SARS-CoV-2 IGRA (Qiagen, Germany) according to the manufacturer's instructions. 19 After tube processing and incubation, analysis was done on a LIAISON XL fully automated chemiluminescence analyzer (Diasorin, Italy). Pre-validated cut-offs for antigen specific responses were defined to be ≥0.101 IU/mL and ≥0.145 IU/mL for CD4 (Ag1) and CD4/CD8 (Ag2) T cells, respectively, after subtraction of background (Nil).

Results < 0.03 IU/mL was considered a non-response. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint

Nasopharyngeal swabs were frozen at -20ºC upon arrival, thawed, and inactivated at 56ºC for 30 min. Bacteriophage MS2 (Roche, Switzerland) was added to samples as extraction/inhibition control. Nasopharynx samples (200 uL) were extracted on the 

Differences in categorical demographics, routine biochemistry according to reference limits and symptom scores were analyzed with chi-square or Fisher's exact test. Differences in age and BMI were compared using students T-test. Biochemical data and markers of immune activation and inflammation were compared with non-parametric tests; Kruskal-Wallis a priori if >2 groups (i.e. when the control group was included) and Mann-Whitney when two groups. When adjustment for covariates was necessary, ANCOVA was used (e.g., when assessing virus load between Omicron and Delta using symptom days as covariate). We used All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint a linear mixed model to assess the association between virus load (log10 transformed) and symptom days with a random intercept by subject to control for repeated measures.

Significance of difference in antibody levels and interferon gamma release was tested using Wilcoxon Signed-Rank Test for paired samples or Mann-Whitney with help of the Excel plugin Realstats. P-values are two-sided and considered significant when <0.05 (Supplemental Table 1 ).

Demographics and clinical characteristics at inclusion of the COVID-19 patients infected with Omicron (n=52) or Delta (n=18) variants is shown in Table 1 . Overall, the characteristics, including symptom duration before diagnosis, were similar between the two groups. Median age was approximately 40 years, and 80% were <50 years of age. There were few comorbidities and no patients reported the use of immuno-suppressive drugs. All but one had received at least one dose of an mRNA COVID-19 vaccine, and 65 had received ≥2 doses ( Table 1) . One individual with Omicron and two with Delta had received a third dose. Five patients with Omicron, but none with Delta, reported previous COVID-19. Information about vaccine status was obtained for 13 out of 14 healthy controls. All had received two doses, one had received a booster dose, and one reported previous COVID-19 (Supplemental Table 1 ).

Most patients experienced mild symptoms with nasal symptoms, cough being the most frequent (67-78%) ( Table 2) . Around 50% experienced fever and around 5% high fever (>39ºC). None of the patients needed hospitalization. There were few differences in symptoms between Omicron and Delta infected patients. However, while smell/taste All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint symptoms were frequent in Delta patients (72%) they were infrequent in Omicron patients (15%, p<0.001). A larger proportion of Delta patients experienced concentration difficulties ("brain fog", 33%) compared to Omicron patients (10%, p=0.017).

Using a mixed model adjusting for repeated measures, viral load in nasopharynx was inversely correlated with time since symptom debut (t=-3.9, p<0.001) (Figure 1A) , showing no differences in the slopes between Omicron and Delta variants. However, after adjusting for time since symptom onset, viral load was significantly higher in patients infected with Omicron at 1 week follow-up, compared with those infected with the Delta variant, reflecting that all Delta infected patients had undetectable virus ( Figure 1B) . Importantly, however, as many as 80% of Omicron patients had undetectable virus levels at this time point.

Most measures, including hematology, liver enzymes, kidney function, and cardiac markers, were normal, and the 0-15% outside reference limits were only marginally elevated (Supplemental Table 2 ). Between 25-30% had elevated CRP and fibrinogen at inclusion, which normalized at 1 week. There were no differences in routine biochemistry between Omicron and Delta patients, except higher IgA levels in the Delta group at inclusion and one

week, but with no difference in the proportion of patients with IgA outside reference levels between the groups. In the patient group as a whole, those with smell/taste symptoms had higher IgA levels than those without these symptoms at inclusion (median 2.4 g/L vs. 1.9 g/L, p=0.021) with a similar trend at 1-week (2.2 g/L vs. 1.8 g/L, p=0.054).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in We measured plasma levels for a wide range of markers of inflammation and immune activation at inclusion and one-week follow up, according to Omicron-or Delta infection and in healthy controls (Supplemental Table 3 ). A few markers were increased at inclusion as compared to healthy controls. Thus, the monocyte/macrophage activation markers sCD14 and sCD163, the acute phase markers LBP and PTX-3, IP-10 with activating effects on T cells, and the fibrosis marker GDF-15 were all elevated compared with controls, but with no differences between Omicron and Delta (Supplemental Table 3 ). These markers returned to levels comparable to controls after one week, except PTX-3 that remained elevated in patients with Delta infection after one week, and GDF-15 that remained elevated in both groups (Supplemental Table 3 ).

Whole blood IFN-γ release assays were used for indirect detection of spike-reactive T-cells.

Levels of secreted IFN-γ was similar in individuals infected with Omicron and Delta, and higher than observed in healthy vaccinated controls ( Fig. 2A) . There were no time-dependent changes in INF-γ release between inclusion and at one week follow-up. Collectively, these results suggest that memory T-cells were expanded at a very early stage during infection.

All but one study participant was positive for anti-RBD antibodies, and the majority had titers higher than 4000 BAU (Figure 2B-C, Supplemental Table 1) . A total of 69 sera were tested for neutralizing activity against vaccine ancestral SARS-CoV-2. The median titer was 450 (range 28-640), and the correlation with BAU was 0·77 (Supplemental Table 1 ). Infection with Omicron or Delta led to a modest and similar time-dependent increase in anti-RBD titers All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint (Figure 2B-C) . The two groups also had a similar increase in IgA antibodies to RBD and IgG antibodies to nucleocapsid (Figure 2B-C) . High levels of IgG antibodies to RBD were also found in samples from healthy vaccinated controls, whereas anti-RBD IgA and antinucleocapsid IgG were nearly undetectable ( Figure 2D) . Figure 3C) . These all had self-reported previous COVID-19 (Supplemental Table   1 ).

One participant infected with Omicron was unvaccinated and had no previous history of COVID-19 (Figure 3, black enlarged dots) . This individual cleared the virus at day 16 ( Figure 3A) . Antibodies to Wuhan RBD, nucleocapsid, or IFN-γ release, were not detected, but reactivity with Omicron RBD was detected at day 16 ( Figure 3B-F) . Interestingly, there were high levels of antibodies to full length Spike protein (Wuhan) in the first sample ( Figure   4A ). There was also a high level of antibodies to the S2 domain of the seasonal coronavirus OC43, and to two peptides that are conserved in the S2 domains of SARS-CoV-2 and OC43 ( Figure 4A-B) . However, there were no elevation of antibodies to the S1 domains of spike from OC43 or HKU1 or to influenza or rhinovirus (Figure 4D-E) .

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The methods used here do not discriminate between primary and recall responses to the SARS-CoV-2 spike protein. Yet, results obtained for antibodies specific for the nucleocapsid protein suggest that the contribution of primary responses was modest. There was a statistically significant increase in anti-nucleocapsid antibodies over time, but except for those with a prior history of COVID-19, the levels remained near the detection limit in most individuals throughout the observation period. The levels of spike peptide-induced IFN-γ release from T-cells were higher than those observed in samples from healthy controls already at 2-10 days after symptom onset. This is well below the time range expected for a primary Tcell response. It therefore is reasonable to conclude that virus clearance was mainly mediated through recall responses.

Results obtained from the single unvaccinated individual infected with Omicron should be interpreted with great caution, but they are nevertheless interesting. The selective IgG reactivity to Omicron RBD at day 16 suggests that infection with this variant does not necessarily lead generation of to antibodies that neutralize other variants. The high levels of antibodies to full-length spike protein from the Wuhan variant at day 9 is likely to be directed to the S2 domain. While we did not have access to pre-infection samples, we have previously shown that antibodies to the full-length spike protein are rarely found in pre-pandemic samples. 13 It is also worth noting that the unvaccinated study participant with Omicron infection had very high levels of antibodies to the S2 domain of seasonal coronavirus OC43, and to peptide epitopes in S2 that are conserved between SARS-CoV-2 and OC43. The most likely explanation for reactivity to the full-length spike protein at day 9 is therefore a cross-All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint reactive recall response. While this was only observed in a single individual, the rapid clearance of virus may indicate that cross-reactive S2-reactive antibodies developed during infection with seasonal coronaviruses in some cases can be broadly protective.

It is important to note that the cohort consisted of otherwise healthy individuals, the majority younger than 50 years of age, and that the median time since the second vaccine dose was only 3.8 months (Supplemental Table 1 ). While we did not have a true baseline, the median titer of anti-RBD antibodies in the first set of samples was higher than 4000 BAU, which was found to correspond to a neutralization titer of 450 against ancestral vaccine SARS-CoV-2 (Supplemental Table 1 ). Thus, the immune status in this cohort is probably well above the average for people who have received two doses of mRNA vaccines during 2021. Yet, the levels are probably not higher than what is obtained in older individuals after a booster dose.

The four participants who had received a booster dose had anti-RBD antibody titers in the range of 8000-16000 BAU (Supplemental Table 1 ).

It is well established that vaccination of COVID-19 convalescents results in strong and lasting immunity. Less is known about the immunity obtained when vaccinated individuals are infected. Here, we show that the levels of antibodies to the nucleocapsid protein remain low during the first two weeks after vaccinated individuals were infected with Delta or Omicron.

Longer observation periods are necessary to firmly establish the level of immunity that is obtained. Yet, it seems possible that vaccinated individuals may clear the virus before they mount a strong primary immune response. This possibility should be addressed in studies with longer follow up times.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in vaccines. Omicron evasion from humoral immunity may therefore be less severe than indicated from results of in vitro virus neutralization assays.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The table is based on self-report of symptoms through a questionnaire and lists all symptoms reported from disease onset to inclusion in the study.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Table 1 .

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.27.22269895 doi: medRxiv preprint

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Divergent SARS CoV-2 Omicron-specific Tand B-cell responses in COVID-19 vaccine recipients

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway

What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol

Rapid SARS-CoV-2 variant monitoring using PCR confirmed by whole genome sequencing in a high-volume diagnostic laboratory

An international serum standard for application in assays to detect human complement activation products

Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

A serological assay to detect SARS-CoV-2 seroconversion in humans

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

Viral epitope profiling of COVID-19 patients reveals crossreactivity and correlates of severity

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data

Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron

The authors would like to thank Cathrine Fladeby for providing professional support with virus quantification. We thank Roger Eugen Poliakov Egseth for technical support.